Donna See

Donna is the founding CEO of Xora Innovation, an early-stage investing platform of Temasek. Donna brings to bear over 20 years of experience in the nuanced process of transforming raw scientific and engineering innovation into commercially viable ventures. Previously, she served in start-up and founding executive roles, including Chief Business Officer of TARA Biosystems, a venture-backed cardiac precision medicine company, acquired by Flagship Pioneering’s Valo Health to accelerate AI-enabled drug discovery of cardiovascular medicines; co-founder of Vixen Pharmaceuticals, a founder-led specialty autoimmune company whose ground-breaking work is benefiting alopecia areata patients worldwide (sold by Eli Lilly under the tradename Olumiant®); and Chief Business Officer of Allied-Bristol Life Sciences, a joint venture of Allied Minds and Bristol-Myers Squibb (NYSE: BMS), which developed therapeutic assets from leading U.S. academic labs. Prior to that, at Columbia Technology Ventures, she directed monetization and commercialization of a portfolio of over 2,000 assets (via licensing, patent pools, patent auctions, patent assertion/litigation, and university spinouts), from engineering, basic sciences and clinical labs at Columbia University. She was previously on the technology ‘buy side’ at New York-Presbyterian Hospital, where she was involved with the assessment and development of new clinical technologies and business opportunities. Earlier in her career, Donna worked on public-private healthcare initiatives with the U.S. Centers for Disease Control, the U.S. Public Health Service, Departments of Health (in San Francisco, Hawaii, and New York City) and at the World Bank. Donna received her MBA and MPH (in Health Policy) from Columbia University and holds a BA in the Natural Sciences from The Johns Hopkins University.